The first among Indian pharmaceutical companies to realise and embrace the importance of innovation, we invest 6–8% of global revenues annually into Research and Development (R&D). With a team of over 2,900 R&D personnel with strong intellectual capabilities in formulations, process chemistry, and analytical development, our strength lies in developing generics and technologically complex products. We specialize in differentiated products including liposomal drugs, inhalers, lyophilized injections, nasal sprays, and controlled-release dosage forms, showcasing our strong focus on innovation.
Recent Posts
- SPIL Q4FY26 Financial Results
- Press Release Sun Pharma reports Q4 & full year results for FY26
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
Recent Comments